To better understand the genetic architecture and adaptability of native sheep, 22 breeds were genotyped using ovine50K SNP chips. Eleven additional populations from open-source repositories were included. Cross population Extended Haplotype Homozygosity (XP-EHH) and Relative Scaled Haplotype Homozygosity (Rsb) haplotype-based approaches were used to identify genetic variations influencing the adaptation of local sheep breeds to different climatic zones. The results indicate that all breeds exhibited high but declining genetic diversity levels, with a larger proportion of genetic variation explained by development history and refined by geographical origin, as shown by principal component analysis and Neighbor Net graphs. Admixture analysis revealed high admixture levels in European and North African breeds. Using XP-EHH and Rsb methods, 371 genes were putatively under selection, with only nine common among all population pairs, highlighting unique adaptability. Most identified genes, including Interleukin (IL) and cluster differentiation (CD) gene families underlie immune responses, emphasizing their role in resilience to climate change effects. These findings support that indigenous sheep breeds have retained significant genetic diversity, but improper genetic management may threaten it. Additionally, the research emphasizes that indigenous sheep breeds' unique adaptability to specific climatic zones makes them valuable genetic assets for developing climate-resilient breeds.

Background: Undernutrition disorder is a prevalent comorbidity (up to 25%) in type 2 diabetes (T2D) patients which significantly compromises their health. We aimed to assess the association between single nucleotide polymorphysms (SNPs) adiponectin (ADIPOQ) +276 (G/T) and resistin (RETN) -420 (C/G) with the risk of developing T2D and undernutrition in patients with T2D. Methods: The research was conducted as prospective case-control study among 106 patients with T2D and 106 healthy control individuals in the territory of the Bosnia and Herzegovina from Sep 1st 2022 to May 1st 2023. For assessing the nutritional status, the mini nutritional assessment (MNA) was used. DNA analysis was carried out by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) method. The data were analyzed using chi-square test, t-test for independent samples and binary multivariate logistic regression. Results: The research included 212 subjects of which 124 (58.5%) were male. The mean age of the subjects was 68.48±4,67 yr. Almost 20% of subjects were undernourished, significantly more T2D patients when compared to controls (33% vs. 6.6%; P<0.001). ADIPOQ +276 GT genotype was identified as significant predictor of T2D (OR: 3.454; 95% CI: 1.400-8.521; P=0.007) and undernutrition disorder (OR: 3.453; 95% CI: 1.331-8.961; P=0.011) in T2D population, while the presence of RETN -420 CG genotype had protective effect against occurrence of T2D (OR: 0.353; 95% CI: 0.144-0.867; P=0.023). However, RETN genotypes were not associated with undernutrition disorder. Conclusion: ADIPOQ +276 gene polymorphism represent a significant predictor for development of T2D and undernutrition disorder in T2D population, while RETN -420 gene polymorphism was identified as a significant factor associated with a reduced risk for T2D, but was not associated with undernutrition.  

Background: All currently used therapeutic protocols and drugs for Clostridioides difficile infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a therapeutic protocol for a medium–severe form of CDI. In addition, the effects of a modified therapeutic protocol with standard monotherapy on the number of stools and stool consistency in a medium–severe CDI will be compared. Materials and Methods: A prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group of patients was treated with vancomycin monotherapy. The other group was treated with the modified therapeutic protocol (vancomycin + nifuroxazide). Results: The modified therapy with vancomycin + nifuroxazide demonstrated enhanced pharmacological efficacy in the management of CDI compared to the standard vancomycin monotherapy. Patients treated with dual therapy reported a significantly lower number of stools in first, second and third control; first control (4.47 ± 2.20 compared to 5.70 ± 1.91 in vancomycin group (p = 0.024)), second control (2.37 ± 0.85 compared to 3.13 ± 0.90 in vancomycin group (p = 0.001)), and third control (1.53 ± 0.51 compared to 1.80 ± 0.61 in vancomycin group (p = 0.035)). Also, the first and third controls noted significant improvements in stool consistency, measured as a decrease in the number of completely watery stools (p = 0.011 and p < 0.001, respectively). Conclusions: Nifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium–severe form of CDI.

Introduction Prisoners are at a higher risk of communicable diseases (such as HIV and hepatitis) than the general population. Therefore, medical screening is crucial for early diagnosis, treatment, identifying those at higher risk of infection, and prevention of infection spread. Objective The main objective of this study was to analyze the factors associated with hepatitis B and C seropositivity in the prison population in Montenegro in two consecutive study years. Method Prisoners of Prison for Short and Long prison terms in Spuž, Montenegro, were included in two cross-sectional studies during 2012 and 2021. Data on socio-demographic factors, risky behavior, and preventive measures related to blood-borne viruses were collected. The data were statistically processed by statistical testing of differences and applying regression models in SPSS Windows, version 19. Results A total of 506 prisoners (2012–298; 2021–208) were included in this study. One fifth of prisoners were seropositive for viral hepatitis B (2012–0.7%; 2021–3.4%) or C (2012–21.8%; 2021-20.7%) or both (2012–0.33%; 2021–0.0%). Factors associated with viral hepatitis B and C seropositivity in both years were shorter prison terms served and injection drug use. Additionally, factors associated with prisoners seropositivity in 2012 were ever drug use and lack of free hygiene kits in prison, and in 2021 were condom use with a permanent partner, non-condom use with non-permanent partner, and availability of free syringes and needles distribution. Conclusion and recommendation Prevalent risky behaviors and the lack of harm reduction interventions are more common among seropositive prisoners. Establishing a prison hospital, improving the surveillance system, introducing new or improving old harm reduction interventions is imperative.